Assessment of Functional Success Predictors in the Treatment of Exudative AMD: A 3-Year Real-World Study
DOI:
https://doi.org/10.48560/rspo.38177Keywords:
Intravitreal Injections, Macular Degeneration/drug therapy, Wet Macular Degeneration/drug therapy, Vascular Endothelial Growth Factor A/antagonists & inhibitorsAbstract
INTRODUCTION: Intravitreal anti-VEGF therapy has been shown to delay progression of neovascular age-related macular degeneration (nAMD) and reduce the incidence of legal blindness. However, a subset of patients exhibits suboptimal responses, with some experiencing significant vision loss. The underlying causes of this variability remain for the most part unclear. Retrospective studies have so far identified potential predictors of visual outcomes. This study aimed to investigate factors associated with functional success in treatment-naïve nAMD patients receiving anti-VEGF therapy over a 3-year period.
METHODS: A retrospective observational study was conducted at a tertiary center in Coimbra (Portugal), including naïve patients who started treatment with anti-VEGF for nAMD between 2017 and 2020 and completed a 3-year follow-up period. Demographics, best corrected visual acuity (BCVA), time until treatment initiation and OCT features were evaluated. Functional success was defined as achieving driving vision (>69 letters) in 3 years. The effects of baseline clinical and OCT markers on functional success were analyzed at last follow-up using mixed-effects models.
RESULTS: One hundred fourteen eyes from 89 patients were included, of which 56.2% were female. Mean age at inclusion was 76.82 (7.23) years. Thirty-nine eyes (34.2%) achieved functional success at last follow-up. Overall, a significant decrease of mean 5.75 (2.15) letters in BCVA was observed during follow-up, from mean 56.98 (95% CI: 52.7, 61.3) at baseline to 51.23 (95% CI: 46.9, 55.6) letters at 3 years (p=0.009). A mixed-effects model was used to identify predictors of functional success at 3 years. Higher BCVA at baseline predicted a 1.06 (95% CI: 1.03, 1.09) higher odds of achieving functional success. Similarly, the presence of subretinal fluid at baseline had a 4.20 (95% CI: 1.12, 15.69) higher odds of functional success at 3 years. On the other hand, the presence of type 2 neovascularization was associated with a 0.15 (95% CI: 0.03, 0.90) lower odds of achieving functional success.
CONCLUSION: In this study, BCVA and the presence of subretinal fluid at baseline were significant predictors of functional success. Careful evaluation of clinical and OCT features at baseline may enable better prognostic assessments for patients with neovascular AMD treated with anti-VEGF.
Downloads
References
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-Related Macular Degeneration: A Review. JAMA 2024;331:147-57. doi: 10.1001/jama.2023.26074
Emami-Naeini P, Garmo V, Boucher N, Fernando R, Menezes A. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema. Ophthalmol Retina. 2024;8:388-98. doi: 10.1016/j.oret.2023.10.010.
Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K. Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation. Clin Ophthalmol. 2019;13:1981-9. doi: 10.2147/OPTH.S224319.
Ferlov Baselius NJ, Brynskov T, Falk MK, Sørensen TL, Subhi Y. Driving vision in patients with neovascular AMD in anti-VEGF treatment. Acta Ophthalmol. 2021;99:e1360-5. doi: 10.1111/aos.14831.
Zhang X, Lai TYY. Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration. Biomed Res Int. 2018;2018:9640131. doi: 10.1155/2018/9640131.
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, et al. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration. Ophthalmol Retina. 2024;8:350-9. doi: 10.1016/j.oret.2023.10.022.
Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, et al. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. Invest Ophthalmol Vis Sci. 2015;56:5040-7. doi: 10.1167/iovs.15-16494.
Phan LT, Broadhead GK, Hong TH, Chang AA. Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration - Current Perspectives. Clin Ophthalmol. 2021;15:3351-67. doi: 10.2147/OPTH.S205147
Borkenstein AF, Borkenstein EM, Persson S, Muus G, Nielsen NV. Improving Outcomes for Patients with Age-Related Macular Degeneration and Cataracts: The Importance of Including an Assessment of Activities of Daily Life (ADL). Clin Ophthalmol. 2021;15:3333-9. doi: 10.2147/OPTH.S327274
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista Sociedade Portuguesa de Oftalmologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.
To obtain the Conflict of Interest file, click here
